Mark T Reding

Associate Professor, Medicine - Hematology, Oncology, Transplant

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Expertise related to UN SDGs

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

Fingerprint

Dive into the research topics where Mark T Reding is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

5 Active
31 Finished

A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg inHemophilia A Patients with Residual FVIII Levels
Reding, M. T.
BIOMARIN PHARMACEUTICAL, INC.
7/15/18 → 7/15/23
Project: Research project
Health Resources and Services Administration Grant
Reding, M. T.
Fairview Health Services
6/1/18 → 5/31/21
Project: Research project
A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels...
Reding, M. T.
BIOMARIN PHARMACEUTICAL, INC.
5/1/18 → 7/15/23
Project: Research project
A Prospective Non-Interventional Study of Bleed
Reding, M. T.
BIOMARIN PHARMACEUTICAL, INC.
2/15/18 → 12/31/23
Project: Research project
ECHO: Expanding Communications on Hemophilia-A Outcomes.
Reding, M. T.
BAYER HEALTHCARE PHARMACEUTICALS
7/1/16 → 12/31/21
Project: Research project

38 Article
7 Review article
2 Letter
1 Chapter

Opioid exposure in haemophilia patients is common and underreported
Peltier, S. J., Mazepa, M. A., Freese, R. L., Nelson, S. F., Kearney, S. L. & Reding, M. T., Mar 2020, In: Haemophilia. 26, 2, p. 251-256 6 p.
Research output: Contribution to journal › Article › peer-review
Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027
Reding, M. T., Pabinger, I., Lalezari, S., Santagostino, E. & Mancuso, M. E., Jul 1 2020, In: Haemophilia. 26, 4, p. e201-e204
Research output: Contribution to journal › Letter › peer-review

Open Access
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
Lalezari, S., Reding, M. T., Pabinger, I., Holme, P. A., Negrier, C., Chalasani, P., Shin, H. J., Wang, M., Tseneklidou-Stoeter, D. & Maas Enriquez, M., Nov 1 2019, In: Haemophilia. 25, 6, p. 1011-1019 9 p.
Research output: Contribution to journal › Article › peer-review

Open Access
3 Scopus citations
Reversal of acquired von Willebrand syndrome with allogeneic stem cell transplant for chronic lymphocytic leukemia
Hegerova, L., He, F., Zantek, N. D., Vercellotti, G. M., Holtan, S. G. & Reding, M. T., Jul 2019, In: Blood Cells, Molecules, and Diseases. 77, p. 109-112 4 p.
Research output: Contribution to journal › Article › peer-review
Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial
Santagostino, E., Lalezari, S., Reding, M. T., Ducore, J., Ng, H. J., Poulsen, L. H., Michaels, L. A. & Linardi, C. C. G., Nov 2019, In: Thrombosis Research. 183, p. 13-19 7 p.
Research output: Contribution to journal › Article › peer-review

Open Access
5 Scopus citations